Increasing Quinolone Resistance in Salmonella
enterica serotype Enteritidis by Mølbak, Kåre et al.
DISPATCHES
514 Emerging Infectious Diseases  •  Vol. 8, No. 5, May 2002
Increasing
Quinolone
Resistance in
Salmonella enterica
Serotype Enteritidis
Kåre Mølbak,* Peter Gerner-Smidt,* 
and Henrik C. Wegener† 
Until recently, Salmonella enterica serotype Enteritidis has
remained sensitive to most antibiotics. However, national sur-
veillance data from Denmark show that quinolone resistance in
S. Enteritidis has increased from 0.8% in 1995 to 8.5% in 2000.
These data support concerns that the current use of quinolone
in food animals leads to increasing resistance in S. Enteritidis
and that action should be taken to limit such use. 
almonella enterica serotype Enteritidis is the most com-
mon cause of foodborne salmonellosis worldwide. Histori-
cally, this serotype has remained sensitive to most antibiotics,
unlike other common serotypes such as Typhimurium, Hadar,
Virchow, and Infantis, in which resistance to a wide range of
antimicrobial agents is common (1). Recently in Denmark, we
have recorded increasing resistance to quinolones in S. Enterit-
idis from human infections. This finding is cause for concern
because fluoroquinolones are first-line drugs for treatment of
human salmonellosis. 
The Study
From 1995 to 2000, 13,334 S. Enteritidis infections were
recorded in Denmark, accounting for 62% of all zoonotic sal-
monella infections. To monitor drug resistance (2), we exam-
ined a random sample of 2,546 isolates, of which 82 (3.2%)
were resistant to the quinolone nalidixic acid. These data
showed that quinolone resistance increased from 0.8% (3 of
384 isolates) in 1995 to 8.5% (31 of 366) in 2000 (Figure).
Resistance to other antimicrobial agents was infrequent, and
quinolone resistance was mainly present as a single resistance.
Quinolone resistance was related to foreign travel as well
as S. Enteritidis phage type (PT). In isolates from patients with
a known history of foreign travel, 8.9% were resistant, com-
pared with 2.4% in domestically acquired infections
(p<0.0001; Table). In 157 patients who had returned from a
European destination (excluding Scandinavia), 18 (11.5%) had
resistant isolates. Resistance was highest in  patients returning
from Spain: 12 (19.7%) of 61 isolates were resistant. Five
(7.5%) resistant strains were found in 67 isolates from Asia
(mainly Turkey and Thailand), but no resistant strains were
recovered from 25 persons who had traveled to Africa. Five
patients had visited other countries (1 resistant strain), and we
had no information about the destination for the remaining 48
patients (3 resistant strains).
The major sources of domestically acquired S. Enteritidis
infections are raw or undercooked eggs produced in Denmark
(3, unpub. data). The most common phage types in Danish
layer hens are PT 6 and PT 8, which accounted for 65.1% of
the domestically acquired infections in our study. Resistance in
these two phage types remained low (Table), as were the rates
of resistance in PT 13A, PT 25, and PT 34. These types also
originate from layer hens. In contrast, the proportion of resis-
tant isolates was highest in phage types PT 1, PT 4, PT 6A, PT
14B, and PT 21, which are often associated with infections
from imported poultry products, including imported broiler
chickens.
From 1994 to 1997 in England and Wales, quinolone resis-
tance in S. Enteritidis increased from 0.4 % to 1.3%. As in our
study, resistance was highest in PT 1 (19%) and PT 6A (14%)
(4). These types were mainly associated with foreign travel. In
a recent study from Spain, 31% of 385 S. Enteritidis isolates
overall but 80% of PT 1 isolates were reported to be quinolone
resistant (5).
Conclusions
The emergence of quinolone resistance in the most com-
mon salmonella serotype worldwide is a serious public health
concern. Resistance to nalidixic acid has been associated with
reduced efficacy of fluoroquinolones such as ciprofloxacin
(6,7). The use of nalidixic acid or fluoroquinolones in humans
is unlikely to contribute substantially to the increase in resis-
tance, for the following reasons: an antibiotic prescribed in
connection with a physician’s request for a fecal specimen is
unlikely to have affected the resistance pattern because treat-
ment is usually initiated after the specimen is collected. Fluo-
roquinolones are potent bactericidal drugs and are not likely to
select for resistance when therapeutic concentrations are
obtained (8). Nalidixic acid is used in some developing coun-
tries for the treatment of dysentery, but the this practice is
unlikely to select for quinolone-resistant S. Enteritidis in the
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zoonotic reservoir. The prevalence of resistance in S. Enteriti-
dis was, in our study, highest in patients returning from devel-
oped countries. Furthermore, fluoroquinolones are not used to
treat children. In children <15 years of age, the prevalence of
quinolone-resistant strains was 9.5% (4/42) among patients
with a history of foreign travel and 1.4% (7/499) in domesti-
cally acquired cases. The corresponding figures for adults
were 8.9% (23/260) and 2.7% (47/1,744). Finally, the use of
quinolones in humans could not conceivably be responsible
for the large variation in the prevalence of resistance by phage
type. If the use of quinolones in human medicine contributed
to the emergence of quinolone resistance in S. Enteritidis,
resistance would be found independently of phage type.
Increasing quinolone resistance is not confined to food-
borne salmonella but also includes campylobacters; resistance
is primarily driven by the use of fluoroquinolones in the live-
stock production (8,9). Limited quantities of fluoroquinolones
are currently used in food production in Scandinavia. During
1997-1998, the annual use of the liquid formulation of fluoro-
quinolones for 130 million to 140 million poultry was <150
kg; during 1999-2000, usage decreased to <100 kg (2). Unfor-
tunately, quantitative data on the use of fluoroquinolones are
not available from most areas. Several fluoroquinolones are
licensed and used in other countries of Europe, Southeast Asia,
and the Americas for treatment of food animals, particularly
for mass medication in the poultry industry, mainly for broiler
chickens (2,8-10). Our data support concerns that the current
pattern of quinolone use in food animals leads to increasing
quinolone resistance in S. Enteritidis and that action should be
taken to limit this use.
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Table. Prevalence of quinolone resistance in human isolates of 
Salmonella enterica serotype Enteritidis, by phage type and history of 
foreign travel. Denmark, 1995–2000.
Phage type
No history of foreign travel Foreign travel
No. resistant 
(%)
Total No. resistant 
(%)
Total
1 22 (23.4) 94 11 (29.7) 37
4 7 (2.4) 292 5 (3.8) 131
6 4 (0.5) 765 0 (-) 28
6A 1 (5.9) 17 4 (22.2) 18
8 8 (1.3) 627 0 31
13A 0 (-) 9 0 4
14B 1 (20.0) 5 1 (14.3) 7
21 3 (4.9) 61 0 4
21B 0 (-) 16 0 0
25 0 (-) 19 0 0
34 0 (-) 81 0 2
Others and 
nontypeable
6 (3.9) 152 4 (13.8) 29
Not typed 2 (1.9) 105 2 (18.2) 11
Total 54 (2.4) 2,243 27 (8.9) 302